Dr. Thomas Colletti
The objective of this paper is to analyze the effectiveness of ivermectin, a readily available and cost-effective antiparasitic drug with proposed anti-viral properties, in the treatment and prevention of disease progression in COVID-19-infected patients. Current studies convey a lack of strong evidence-based research to demonstrate a positive correlation between ivermectin use in the treatment and prevention of COVID-19 infection and disease progression, including mortality. Although some studies showed a slight improvement in the prevention of disease progression, the numbers of those cases were not significant enough to convey strong evidence-based support for the use of this antiparasitic agent on COVID-19 infection and disease progression. Therefore, further studies need to be conducted to establish the effectiveness of using ivermectin for this viral infection.
Oni F. Ivermectin Use on COVID-19 Infected Patients. Lynchburg Journal of Medical Science. 2022; 4(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.